tradingkey.logo

Gilead Reports Positive Topline Results From Phase 3 Ascent-04/Keynote-D19 Study

ReutersApr 21, 2025 12:41 PM

- Gilead Sciences Inc GILD.O:

  • TRODELVY® PLUS KEYTRUDA® DEMONSTRATES A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN PROGRESSION FREE SURVIVAL IN PATIENTS WITH PREVIOUSLY UNTREATED PD-L1+ METASTATIC TRIPLE-NEGATIVE BREAST CANCER

  • GILEAD: POSITIVE TOPLINE RESULTS FROM PHASE 3 ASCENT-04/KEYNOTE-D19 STUDY

  • GILEAD: STUDY SHOWED SUPERIORITY OF TRODELVY PLUS KEYTRUDA VERSUS STANDARD OF CARE (SOC) IN 1L METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)

  • GILEAD: STUDY MET MAIN GOAL, WITH STATISTICALLY SIGNIFICANT,CLINICALLY MEANINGFUL IMPROVEMENT IN PFS

  • GILEAD: OVERALL SURVIVAL (OS), KEY SECONDARY ENDPOINT, WASN'T MATURE AT TIME OF PFS PRIMARY ANALYSIS

  • GILEAD: TRODELVY PLUS KEYTRUDA SHOWS EARLY TREND IN IMPROVEMENT FOR OS VERSUS SOC IN PATIENTS WITH PREVIOUSLY UNTREATED PD-L1+ (CPS ≥10) MTNBC

  • GILEAD: WILL CONTINUE TO MONITOR OS OUTCOMES

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI